Vonir, vonir ..

að finnist einhver leið til að skemma dna himnuna utan um virusinn Covid19 sem gefur honum aðgang að frumum okkar sem hann hertekur.

Moderna (MRNA) said in a statement Monday that the first batch of its novel coronavirus vaccine, called mRNA-1273, has been sent to the National Institute of Allergy and Infectious Diseases (NIAID).

Shares in the company, which is located near Boston, were trading 15% higher in New York on Tuesday.

Moderna said the first vials of the experimental vaccine would be used in a planned Phase 1 study in the United States, which typically involves testing a vaccine on a small number of healthy humans.

 

NIAID Director Anthony Fauci said that a clinical trial could start by the end of April, the "first step" in potentially making a vaccine available for use.

The Wall Street Journal, which was first to report the development, said that two doses of the vaccine would be tested on volunteers to see if it produces an immune response that protects against the virus. Fauci told CNN that 45 people would participate in the trial.

 

Even if the clinical trial is successful, further testing and regulatory approvals would be needed before the vaccine could be deployed widely.

Health officials and pharmaceutical companies around the world are working at a breakneck pace to identify treatments or a vaccine to help fight the coronavirus, which has infected more than 80,000 people around the world.

Fauci previously told CNN that researchers could expedite the approval process for a vaccine following a successful Phase 1 trial in an attempt to halt the spread of the virus.

But even when proceeding at an "emergency speed," a vaccine would not be available for use for at least a year or 18 months, he said Tuesday.

 

Moderna is not the only drug company hoping to find an immunization for the virus.

Pharma giants Johnson & Johnson (JNJ) and GlaxoSmithKline (GLAXF) are working on vaccines, as are government scientists including some at NIAID.

Shares in Gilead (GILD) gained nearly 5% on Monday after the World Health Organization said that one of its drugs, remdesivir, is showing signs of helping to treat the coronavirus.

 

While the experimental vaccine developed by Moderna remains unproven, the speed at which it was created represents a breakthrough.

 

According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on the coronavirus.

By comparison, it took researchers about 20 months to start human tests of the vaccine for SARS, an older coronavirus, according to a journal paper written by Fauci.

mRNA vaccines

Moderna has yet to produce a proven vaccine with its mRNA technology platform, which aims to make drugs that direct cells in the body to make proteins to prevent or fight disease. It makes use of messenger ribonucleic acid, a molecule vital to the proper functioning of the body's cells.

 

The technology has had positive results from Phase 1 tests across six different vaccines, one of which is currently in a Phase 2 trial, according to a company spokesperson.

The mRNA approach can produce vaccines faster and for less money than traditional methods, according to UK health policy think tank PHG Foundation.

— Paul R. La Monica contributed reporting.

 

Þetta eru vonir mannkynsins á þessum dimmu dögum.

Athugasemdir

[Ómar Geirsson, 22.3.2020 kl. 15:03]

Það er alltaf von  Halldór.

Þess vegna skiptir svo miklu máli að berjast með kjafti og klóm gegn útbreiðslu veirunnar.

Líkt og flest sýkt lönd heims virðast vera farin að gera nema Svíarnir, þeir þurfa að fækka gamla fólkinu til að rýma fyrir flóttafólkinu á fjárlögunum.

Reyndar kaldhæðni en þannig virkar sauðsháttur þeirra.

Við fáum tíðindi í kvöld, vonandi er stigið skrefið alla leið, annars þarf bara að halda áfram að bögga samstöðuna um ótímabæran dauða samborgara okkar.

Það hlýtur að vera hægt að gera það sem þarf að gera svo sem flestir lifi af þennan faraldur.

Lækningin kemur, og það er miklu styttra í hana en margan grunar.

Kveðja að austan.

[Halldór Jónsson, 23.3.2020 kl. 10:40]

Fitusýrugreinin í Mogga í dag var afbragðs innlegg

[Ómar Geirsson, 24.3.2020 kl. 06:49]

Já Halldór, ég held að þessar fréttir munu leita okkur uppi, en ekki öfugt.

Á þessu augnabliki eru svo margir að leita lausna, og þó kannski ekki hin endanlega sé í sjónmáli, eða það virðist ekki vera, þá safnast í þekkingarbankann og hægt að byggja frekari rannsóknir á því sem þegar er komið.

Og þetta gerist hratt því það er svo mikið undir.

Þess vegna er það besta sem við gerum ónæmiskerfinu okkar er að bíða eftir að góðu fréttirnar leiti okkur uppi í stað þess að við leitum uppi vonbrigðin.

Þau eru þarna, við vitum það.

En það er bara ekki þau sem skipta máli.

Kveðja að austan.